UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

 
FORM 8-K
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 
Date of Report (Date of earliest event reported): February 19, 2009
 
THE DOW CHEMICAL COMPANY
(Exact name of Registrant as specified in its charter)
 
Delaware
(State or other jurisdiction
of incorporation)
1-3433
Commission File Number
38-1285128
(IRS Employer
Identification No.)
 
 
 
2030 Dow Center, Midland, Michigan
(Address of principal executive offices)
48674
(Zip code)
   
   
   
(989) 636-1000
(Registrant’s telephone number, including area code)
 
N.A.
(Former name or former address, if changed since last report)

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 


 
 
Item 8.01 
Other Events
 
As previously disclosed, on November 28, 2008, The Dow Chemical Company entered into a Joint Venture Formation Agreement (the “JVFA”) with Petrochemical Industries Company (K.S.C.), a wholly owned subsidiary of Kuwait Petroleum Corporation.
 
The JVFA is attached as Exhibit 2.1 hereto and incorporated herein by reference.
 

 
Item 9.01 
Financial Statements and Exhibits
 
(d) Exhibits
 
Exhibit No.
Description
 
2.1 
Joint Venture Formation Agreement, dated November 28, 2008, between The Dow Chemical Company and Petrochemical Industries Company (K.S.C.) (portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission as part of an application for confidential treatment pursuant to the Securities Exchange Act of 1934, as amended)
 
 
 
 
 
 
 

 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated:  February 19, 2009
 
 
  The Dow Chemical Company  
         
         
 
By:   /s/ CHARLES J. KALIL  
    Name:   Charles J. Kalil  
    Title: 
Executive Vice President,
Corporate Secretary and General Counsel